DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study
Clicks: 124
ID: 274584
2021
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
1.8
/100
6 views
6 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Immunocompromised adults with severe parainfluenza received nebulized DAS181 or placebo for up to 10 days. The primary endpoint was not met, but a subgroup of s
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (25 words).
Try re-searching for a better abstract.
| Reference Key |
f2021clinicaldas181
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chemaly, Roy F;Marty, Francisco M;Wolfe, Cameron R;Lawrence, Steven J;Dadwal, Sanjeet;Soave, Rosemary;Farthing, Jason;Hawley, Stephen;Montanez, Paul;Hwang, Jimmy;Ho, Jennifer Hui-Chun;Lewis, Stanley;Wang, George;Boeckh, Michael; |
| Journal | clinical infectious diseases |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.